LOXITANE IM (loxapine hydrochloride) by Teva is clinical pharmacology pharmacodynamics: pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. Approved for schizophrenia. First approved in 1979.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
LOXITANE IM is an intramuscular injectable antipsychotic containing loxapine hydrochloride, approved in 1979 for treating schizophrenia. The drug's exact mechanism is not fully established, but it produces tranquilization and suppression of aggressive behavior through effects on subcortical inhibitory areas, with sedation onset within 20-30 minutes. Loxapine is rapidly metabolized and excreted primarily within 24 hours.
Product approaching loss of exclusivity with moderate competitive pressure (30/100) signals potential team consolidation and transition focus from growth to retention and manufacturing efficiency.
CLINICAL PHARMACOLOGY Pharmacodynamics: Pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. However, changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such…
Worked on LOXITANE IM at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LOXITANE IM offers limited career growth due to zero linked job openings and approaching loss of exclusivity; roles focus on defending market share and managing decline rather than launching or scaling. This position suits professionals seeking stable, operations-focused work in a mature product rather than high-growth opportunity.